Biomea Fusion (BMEA) Capital Expenditures (2020 - 2025)
Biomea Fusion (BMEA) posted Capital Expenditures of -$619000.0 for Q4 2025, up 88.01% sequentially from -$5.2 million in Q4 2024, and up 88.01% YoY from -$329232.3 in Q4 2024.
Biomea Fusion (BMEA) Capital Expenditures (2020 - 2025) Analysis & Trends
Biomea Fusion has reported Capital Expenditures for 6 years, with the latest figure at -$619000.0 in Q4 2025.
- Quarterly Capital Expenditures rose 88.01% year-over-year to -$619000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$619000.0 (up 87.33% YoY) and the FY2025 annual result came in at -$619000.0, up 87.33% from the prior year.
- Capital Expenditures grew to -$619000.0 in Q4 2025 per BMEA's latest filing, from -$5.2 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $2.9 million in Q1 2023 and troughed at -$5.2 million in Q4 2024.
- A 5-year average of $62117.6 and a median of $95000.0 in 2022 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures soared 2958.95% in 2023, then slumped 414.34% in 2024.
- Over 5 years, Capital Expenditures stood at $293000.0 in 2021, then jumped by 143.0% to $712000.0 in 2022, then tumbled by 241.01% to -$1.0 million in 2023, then plunged by 414.34% to -$5.2 million in 2024, then jumped by 88.01% to -$619000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$619000.0, -$5.2 million, and $186000.0 for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -619,000.00 |
| Dec 31, 2025 | -619,000.00 |
| Dec 31, 2024 | -5.16 Mn |
| Dec 31, 2024 | -5.16 Mn |
| Sep 30, 2024 | 186,000.00 |
| Sep 30, 2024 | 186,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Mar 31, 2024 | 35,000.00 |
| Mar 31, 2024 | 35,000.00 |
| Dec 31, 2023 | -1.00 Mn |
| Dec 31, 2023 | -1.00 Mn |
| Sep 30, 2023 | 39,000.00 |
| Sep 30, 2023 | 39,000.00 |
| Jun 30, 2023 | 417,000.00 |
| Jun 30, 2023 | 417,000.00 |
| Mar 31, 2023 | 2.91 Mn |
| Mar 31, 2023 | 2.91 Mn |
| Dec 31, 2022 | 712,000.00 |
| Dec 31, 2022 | 712,000.00 |